Proteomics International Reports $2.6M Cash Outflow Amid Commercial Shift

Strategic Pivot to Commercialisation

Proteomics International Laboratories Ltd (ASX:PIQ) is accelerating its transition from a research-driven entity to a commercially focused diagnostics company. The Perth-based biotech is advancing a portfolio of clinically validated proteomics-based diagnostic tests through a disciplined commercial rollout strategy, prioritising capital efficiency and operational readiness.

The company has embraced a distributor-led business model, aiming to leverage established diagnostic networks to accelerate adoption, reduce execution risk, and avoid the costs associated with direct sales infrastructure. This approach supports seamless integration into existing clinical workflows, with Proteomics International retaining oversight of quality control and regulatory compliance.

Diagnostic Portfolio with Market Potential

Proteomics International’s innovation pipeline features four key tests addressing significant unmet clinical needs: Promarker D for early detection of diabetes-related chronic kidney disease; Promarker Eso, a minimally invasive blood test to rule out oesophageal adenocarcinoma in chronic reflux patients; Promarker Endo, a diagnostic for suspected endometriosis; and OxiDx, a platform measuring oxidative stress in specialised applications.

Each test has demonstrated validated clinical performance, with sensitivity and specificity metrics ranging from 76% to 98%, and ongoing validation across independent cohorts. The company estimates realistic medium-term commercial opportunities of approximately 20,000 to 360,000 annual tests in Australia and the US, depending on the indication.

Proteomics is actively appointing distributors in Australia and the US, refining assays, and expanding laboratory capacity to meet anticipated demand. The company is also engaging clinical advisory boards to raise awareness and support market access initiatives.

Reimbursement Pathways in Australia and US

Securing reimbursement is a central pillar of Proteomics International’s commercial strategy. In Australia, the company is targeting Medicare Benefits Schedule (MBS) listing through the Medical Services Advisory Committee (MSAC), a process that involves accumulating clinical and health economic evidence. MBS listing would provide nationwide accessibility and drive volume growth, though timelines are acknowledged as lengthy.

In the US, reimbursement is fragmented across Medicare, Medicaid, and private payers. Proteomics is navigating this complexity by pursuing early private pay options and hospital network coverage while preparing dossiers for Medicare Molecular Diagnostic Services Program (MolDX) review. The company holds key patents and has obtained a CMS Proprietary Laboratory Analysis (PLA) code for Promarker D, facilitating Medicare billing.

Organisational Restructure and Leadership Changes

To support this commercial pivot, Proteomics International has completed a significant organisational restructure, reducing its workforce by approximately 25%, which equates to nine roles. This move is expected to deliver annualised cost savings exceeding $1 million, strengthening the cash position and enabling focused investment in priority areas.

Leadership changes include the appointment of David Morris as CEO and Managing Director, effective in early 2026, succeeding founder Dr Richard Lipscombe who retired after more than two decades. The company also appointed Tim Luscombe as CFO in addition to his Company Secretary role, and welcomed the retirement of Non-Executive Director Neville Gardiner. These shifts align with the company’s goal of enhancing execution discipline and commercial effectiveness.

Proteomics reported operating cash outflows of $2.6 million for the quarter ending March 31, 2026, with a closing cash balance of $5.7 million. The company also received $0.7 million from the exercise of listed options, supporting near-term funding needs.

Execution Roadmap and Future Milestones

The company’s three-year strategic roadmap outlines phased market launches starting with Australia, followed by US expansion. Key initiatives include harmonising laboratory and quality systems across jurisdictions, broadening distributor networks, publishing clinical utility and health economic evidence, and progressing reimbursement submissions.

Proteomics International aims to optimise turnaround times, enhance customer experience, and maintain investor confidence through milestone achievements. The company is also exploring strategic growth options to expand its product portfolio and geographic footprint.

This commercial focus builds on prior achievements, including securing patents for the Promarker Eso test in multiple jurisdictions, and obtaining CAP accreditation for its US laboratory, which underpins its US market ambitions. The appointment of David Morris as CEO was a pivotal step in this transition, bringing extensive global healthcare leadership experience to the helm.

Proteomics International’s shift to a distributor model and reimbursement-driven commercialisation underscores the challenges of translating advanced proteomics research into scalable diagnostic solutions. The coming quarters will be critical as the company seeks to convert clinical validation into sustained market penetration and revenue growth.